Crossmark

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Crossref DOI link: https://doi.org/10.1186/s13058-019-1127-y

Published Online: 2019-03-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kennedy, Sean P.

Han, Jeremy Z. R.

Portman, Neil

Nobis, Max

Hastings, Jordan F.

Murphy, Kendelle J.

Latham, Sharissa L.

Cadell, Antonia L.

Miladinovic, Dushan

Marriott, Gabriella R.

O’Donnell, Yolande E. I.

Shearer, Robert F.

Williams, James T.

Munoz, Amaya Garcia

Cox, Thomas R.

Watkins, D. Neil

Saunders, Darren N.

Timpson, Paul

Lim, Elgene

Kolch, Walter

Croucher, David R. http://orcid.org/0000-0003-4965-8674
Funding

Funding for this research was provided by:

Science Foundation Ireland (11/SIRG/B2157, 14/IA/2395)

Cancer Institute NSW (13/FRL/1-02)

Irish Cancer Society (CCRC13GAL)
License Information

Text and Data Mining valid from 2019-03-21
More Information

Article History

Received: 24 October 2018

Accepted: 11 March 2019

First Online: 21 March 2019

Ethics approval and consent to participate

: All in vivo experiments, procedures and endpoints were approved by the Garvan Institute of Medical Research Animal Ethics Committee.

: Not Applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.